ClinicalTrials.gg
CompletedNCT00366899Updated Feb 22, 2013Results posted

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7 valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 13 sites in Italy. Open to participants aged 75 Days to 105 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-22.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
605
Allocation
Randomized
Ages
75 Days to 105 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Italy.

02

Conditions studied

  • Vaccines, Pneumococcal

Keywords

  • Vaccine
  • Infants
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Days to 105 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 3 months (75 to 105 days) at time of enrollment.
  2. Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
  3. Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
  4. Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
  5. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria

Exclusion criteria:

  1. Previous vaccination with licensed or pneumococcal vaccine.
  2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or vaccines.
  3. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  4. to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
  5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  6. Known or suspected immune deficiency or suppression.
  7. History of culture-proven invasive disease caused by S pneumoniae or Hib.
  8. Major known congenital malformation or serious chronic disorder.
  9. Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
  10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
  11. Participation in another investigational trial. Participation in purely observational studies was acceptable.
  12. Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
605 participants (actual)

Study arms

  • Experimental
    1

    13-valent pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

  • Active comparator
    2

    7-valent pneumococcal conjugate vaccine

    Biological: 7 valent pneumococcal conjugate vaccine

Interventions

  • Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.

  • Biological7 valent pneumococcal conjugate vaccine

    Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  2. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  3. Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose

    Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.

    Time frame: One month after the infant series (6 months of age) and after the toddler dose (12 months of age)

  4. Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

    GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)

    Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)

  5. Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose

    GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.

    Time frame: One month after the infant series (6 months of age) and the toddler dose (12 months of age)

  6. Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

    GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).

    Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)

  7. Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

    GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).

    Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)

  8. Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

    GMC of Polio as measured using a polio in vitro plaque neutralization.

    Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)

  9. Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose

    Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)

  10. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose

    Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose

    Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the toddler dose (12 months of age)

  2. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose

    Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after toddler dose (12 months of age)

Other outcomes

  1. Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose

    Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).

    Time frame: one month after infant series dose 2 and after the toddler dose

  2. Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose

    Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after infant series dose 2 and after the toddler dose

07

Results

Posted Feb 22, 2013

Participant flow

Participants were recruited in Italy from October 2006 to March 2007.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started303303
Vaccinated dose 1302302
Vaccinated dose 2296293
Completed294291
Not completed912
Withdrew: Withdrawal by subject47
Withdrew: Protocol violation21
Withdrew: Failed to return11
Withdrew: Lost to follow-up02
Withdrew: Adverse event01
Withdrew: Physician decision10
Withdrew: Randomized but not consented10
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC7vPnC
Started294291
Completed287282
Not completed79
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject14
Withdrew: Adverse event12
Withdrew: Protocol violation10
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started287282
Completed285281
Not completed21
Withdrew: Withdrawal by subject11
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Local Reactions
Percentage of Participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Toddler Dose7vPnC Toddler Dose
Tenderness - Any (n=234,243,214,215,199,188)32.130.030.436.747.244.1
Tenderness-Significant (n=224,231,199,199,164,153)2.73.54.55.08.55.9
Swelling - Any (n=232,240,207,209,175,165)19.019.624.628.728.627.3
Swelling - Mild (n=232,240,207,208,174,161)17.718.321.726.426.421.7
Swelling - Moderate (n=223,229,198,195,160,157)3.63.15.65.17.510.2
Swelling - Severe (n=222,229,197,194,159,152)0.00.00.00.00.00.0
Redness - Any (n=233,245,213,212,178,174)25.826.531.534.436.536.2
Redness - Mild (n=233,244,211,211,178,172)24.024.628.432.232.630.8
Redness - Moderate (n=222,231,200,195,160,156)2.73.05.53.67.510.9
Redness - Severe (n=243,255,197,194,159,152)0.00.00.00.00.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Systemic Events
Percentage of Participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Toddler Dose7vPnC Toddler Dose
Fever ≥38°C but ≤39°C (n=247,246,227,226,204,197)41.738.655.560.663.752.3
Fever >39°C but ≤40°C (n=224,233,204,201,167,160)3.64.76.97.09.612.5
Fever >40°C (n=222,230,198,195,160,152)0.00.00.00.00.00.7
Decreased appetite (n=246,248,220,218,198,197)35.434.347.345.452.057.4
Irritability (n=258,259,245,243,221,227)72.963.775.575.374.774.9
Increased sleep (n=269,276,226,232,195,196)65.864.557.156.553.854.6
Decreased sleep (n=244,242,222,213,180,171)39.336.440.141.835.635.7
Meds-treat symptoms (n=244,245,219,109,192,190)34.830.643.447.853.143.7
Meds-prevent symptoms (n=230,238,208,208,172,169)12.618.120.224.527.924.3
PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose

Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.

Time frame:
One month after the infant series (6 months of age) and after the toddler dose (12 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose
percentage of participants13vPnC After 2-Dose Infant Series7vPnC After 2-Dose Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Pertussis, PT ≥5 EU/mL (n=250,272,235,219)99.6 (97.8 to 100.0)100.0 (98.7 to 100.0)100.0 (98.4 to 100.0)100.0 (98.3 to 100.0)
Pertussis, FHA ≥5 EU/mL (n=243,272,229,214)100.0 (98.5 to 100.0)100.0 (98.7 to 100.0)100.0 (98.4 to 100.0)100.0 (98.3 to 100.0)
Pertussis, FHA ≥7.82 EU/mL (n=243,272,229,214)100.0 (98.5 to 100.0)100.0 (98.7 to 100.0)100.0 (98.4 to 100.0)100.0 (98.3 to 100.0)
Pertactin ≥5 EU/mL (n=248,270,234,217)100.0 (98.5 to 100.0)100.0 (98.6 to 100.0)100.0 (98.4 to 100.0)100.0 (98.3 to 100.0)
Hepatitis B ≥ 10.0 mIU/mL93.8 (90.2 to 96.3)93.1 (89.5 to 95.8)98.40 (96.00 to 99.60)98.80 (96.60 to 99.80)
Haemophilus Influenzae type b 0.15 μg/ml87.0 (82.0 to 91.1)90.3 (86.1 to 93.5)99.6 (97.7 to 100.0)98.2 (95.4 to 99.5)
Haemophilus Influenzae type b 1.0 μg/ml49.9 (42.7 to 56.0)48.7 (42.6 to 54.9)96.2 (92.9 to 98.2)92.2 (87.8 to 95.4)
Diptheria 0.01 IU/mL (n=207,240,164,190)100.0 (98.2 to 100.0)100.0 (98.5 to 100.0)100.0 (97.8 to 100.0)100.0 (98.1 to 100.0)
Diptheria 0.1 IU/mL (n=207,240,164,190)92.8 (88.3 to 95.9)96.3 (93.0 to 98.3)100.0 (97.8 to 100)100.0 (98.1 to 100.0)
Tetanus 0.1 IU/mL (n=155,214,125,96)94.2 (89.3 to 97.3)92.5 (88.1 to 95.7)97.6 (93.1 to 99.5)93.8 (86.9 to 97.7)
Polio, Type 1 ≥1:899.5 (97.3 to 100.0)99.6 (97.9 to 100.0)100.0 (97.9 to 100.0)100.0 (98.0 to 100.0)
Polio, Type 2 ≥1:895.6 (91.8 to 98.0)96.6 (93.6 to 98.4)100.0 (97.6 to 100.0)100.0 (97.9 to 100.0)
Polio, Type 3 ≥1:899.5 (97.3 to 100.0)98.9 (96.7 to 99.8)100.0 (97.6 to 100.0)100.0 (97.9 to 100.0)
Pertussis, PT (infant ≥16; Toddler ≥21) EU/mL95.2 (91.8 to 97.5)95.2 (92.0 to 97.4)92.8 (88.7 to 95.7)95.4 (91.8 to 97.8)
Pertussis, FHA (Infant ≥31; Toddler ≥162) EU/mL94.7 (91.0 to 97.1)95.6 (92.4 to 97.7)95.2 (91.6 to 97.6)95.3 (91.6 to 97.7)
Pertactin (Infant ≥40; Toddler ≥106) EU/mL91.9 (87.8 to 95.0)95.2 (91.9 to 97.4)94.9 (91.2 to 97.3)95.4 (91.7 to 97.8)
Statistical analysis
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -0.4 · 95% CI -2.2 to 1.0
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.0 · 95% CI -4.0 to 3.8
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.0 · 95% CI -1.6 to 1.4
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.0 · 95% CI -1.6 to 1.4
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -0.90 · 95% CI -5.0 to 2.9
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.0 · 95% CI -1.5 to 1.4
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -3.2 · 95% CI -7.8 to 1.0
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.7 · 95% CI -3.6 to 5.0
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -3.2 · 95% CI -9.1 to 2.4
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.7 · 95% CI -8.2 to 9.5
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.0 · 95% CI -1.8 to 1.6
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -3.5 · 95% CI -8.3 to 0.8
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 1.7 · 95% CI -3.9 to 7.1
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -0.1 · 95% CI -2.3 to 1.7
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: -1.0 · 95% CI -5.0 to 2.8
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Difference: 0.7 · 95% CI -1.6 to 2.9
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.6 to 1.7
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: -2.7 · 95% CI -7.3 to 1.8
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.6 to 1.7
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.6 to 1.7
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: -0.1 · 95% CI -4.3 to 4.1
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -1.6 to 1.7
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: -0.5 · 95% CI -4.7 to 3.7
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: -0.4 · 95% CI -3.0 to 2.0
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 1.4 · 95% CI -0.8 to 4.2
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 4.0 · 95% CI -0.4 to 8.7
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -2.3 to 2.0
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -2.3 to 2.0
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 3.8 · 95% CI -1.7 to 10.9
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -2.4 to 2.1
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -2.4 to 2.1
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: 0.0 · 95% CI -2.4 to 2.1
PrimaryGeometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)

Time frame:
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Reported as:
Geometric mean · EU/mL
Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
EU/mL13vPnC After 2-Dose Infant Series7vPnC After 2-Dose Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Pertussis FHA102.87 (94.35 to 112.16)105.17 (97.25 to 113.73)463.23 (425.19 to 504.67)456.55 (415.06 to 502.18)
Pertussis PT50.01 (45.82 to 54.58)48.44 (44.71 to 52.49)60.89 (55.61 to 66.67)64.53 (59.13 to 70.42)
Pertussis PRN167.76 (149.54 to 188.18)166.19 (150.28 to 183.78)339.30 (309.16 to 372.38)361.70 (328.59 to 398.14)
Statistical analysis
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.98 · 95% CI 0.87 to 1.10
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 1.03 · 95% CI 0.92 to 1.16
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 1.01 · 95% CI 0.87 to 1.17
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 1.01 · 95% CI 0.89 to 1.15
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.94 · 95% CI 0.83 to 1.07
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.94 · 95% CI 0.82 to 1.07
Other pre-specifiedPercentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose

Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).

Time frame:
one month after infant series dose 2 and after the toddler dose
Reported as:
Geometric mean · % Achieving OPA Titer ≥1:8
Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose
% Achieving OPA Titer ≥1:813vPnC After 2-Dose Infant Series13vPnC After Toddler Dose
Common Serotypes - Serotype 4100.0 (96.3 to 100.0)100.0 (95.8 to 100.0)
Common Serotypes - Serotype 6B90.0 (82.4 to 95.1)99.0 (94.3 to 100.0)
Common Serotypes - Serotype 9V100.0 (96.3 to 100.0)100.0 (96.1 to 100.0)
Common Serotypes - Serotype 14100.0 (96.3 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 18C97.0 (91.4 to 99.4)100.0 (96.3 to 100.0)
Common Serotypes - Serotype 19F96.0 (90.1 to 98.9)97.9 (92.7 to 99.7)
Common Serotypes - Serotype 23F97.0 (91.4 to 99.4)100.0 (96.3 to 100.0)
Additional Serotypes - Serotype 194.8 (88.3 to 98.3)100.0 (96.2 to 100.0)
Additional Serotypes - Serotype 399.0 (94.6 to 100.0)100.0 (96.2 to 100.0)
Additional Serotypes - Serotype 596.0 (90.0 to 98.9)100.0 (96.1 to 100.0)
Additional Serotypes - Serotype 6A95.9 (89.9 to 98.9)100.0 (96.2 to 100.0)
Additional Serotypes - Serotype 7F100.0 (96.4 to 100.0)100.0 (96.2 to 100.0)
Additional Serotypes - Serotype 19A95.6 (89.0 to 98.8)100.0 (96.0 to 100.0)
Other pre-specifiedGeometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose

Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after infant series dose 2 and after the toddler dose
Reported as:
Geometric mean · Titers
Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose
Titers13vPnC After 2-Dose Infant Series13vPnC After Toddler Dose
Common Serotypes - Serotype 4526.69 (431.88 to 642.32)1276.21 (1025.09 to 1588.85)
Common Serotypes - Serotype 6B191.34 (133.35 to 274.55)2383.31 (1850.47 to 3069.57)
Common Serotypes - Serotype 9V3585.80 (2787.34 to 4612.99)16384.00 (13066.97 to 20543.06)
Common Serotypes - Serotype 141882.96 (1446.51 to 2451.10)1903.89 (1580.90 to 2292.88)
Common Serotypes - Serotype 18C294.48 (221.80 to 390.98)1324.41 (1063.57 to 1649.22)
Common Serotypes - Serotype 19F222.86 (170.46 to 291.37)391.97 (296.34 to 518.46)
Common Serotypes - Serotype 23F487.51 (356.25 to 667.13)3679.67 (2971.61 to 4556.44)
Additional Serotypes - Serotype 162.63 (47.59 to 82.41)294.07 (226.88 to 381.15)
Additional Serotypes - Serotype 3176.07 (144.89 to 213.96)504.66 (435.71 to 584.53)
Additional Serotypes - Serotype 5127.11 (99.36 to 162.60)333.24 (274.24 to 404.94)
Additional Serotypes - Serotype 6A541.81 (392.09 to 748.68)2217.29 (1821.95 to 2698.42)
Additional Serotypes - Serotype 7F5914.33 (4710.83 to 7425.30)14886.35 (12560.25 to 17643.22)
Additional Serotypes - Serotype 19F157.59 (118.91 to 208.84)1415.08 (1140.56 to 1755.66)
PrimaryGeometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose

GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.

Time frame:
One month after the infant series (6 months of age) and the toddler dose (12 months of age)
Reported as:
Number · mIU/mL
Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose
mIU/mL13vPnC After 2-Dose Infant Series7vPnC After 2-Dose Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose260.46 (214.47 to 316.31)272.67 (220.83 to 336.68)1655.30 (1343.30 to 2039.77)2284.95 (1878.82 to 2778.88)
Statistical analysis
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.96 · 95% CI 0.72 to 1.27
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.72 · 95% CI 0.54 to 0.96
PrimaryGeometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).

Time frame:
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
μg/mL13vPnC After 2-Dose Infant Series7vPnC After 2-Dose Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose0.99 (0.80 to 1.21)1.00 (0.83 to 1.20)9.09 (7.80 to 10.60)8.85 (7.37 to 10.62)
Statistical analysis
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.99 · 95% CI 0.75 to 1.30
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 1.03 · 95% CI 0.81 to 1.30
PrimaryGeometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).

Time frame:
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
IU/mL13vPnC After 2-Dose Infant Series7vPnC After 2-Dose Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Diptheria (n=207,240,164,190)0.52 (0.46 to 0.60)0.67 (0.59 to 0.76)2.77 (2.45 to 3.13)3.71 (3.28 to 4.20)
Tetanus (n=155,214,125,96)0.53 (0.45 to 0.63)0.63 (0.53 to 0.74)2.62 (2.12 to 3.25)2.09 (1.56 to 2.81)
Statistical analysis
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.78 · 95% CI 0.65 to 0.94
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.85 · 95% CI 0.67 to 1.08
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.75 · 95% CI 0.63 to 0.89
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 1.25 · 95% CI 0.88 to 1.79
PrimaryGeometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose

GMC of Polio as measured using a polio in vitro plaque neutralization.

Time frame:
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Reported as:
Geometric mean · Titers
Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
Titers13vPnC After 2-Dose Infant Series7vPnC After 2-Dose Infant Series13vPnC After Toddler Dose7vPnC After Toddler Dose
Polio Type 1 (n=207,262,156,179)180.72 (154.31 to 211.64)207.17 (178.64 to 240.25)924.52 (782.71 to 1092.03)1348.04 (1163.56 to 1561.77)
Polio Type 2 (n=205,262,153,175)123.74 (102.68 to 149.13)130.39 (109.96 to 154.63)1141.62 (958.68 to 1359.47)1340.51 (1147.88 to 1565.48)
Polio Type 3 (n=205,262,153,178)397.32 (327.00 to 482.76)452.14 (382.57 to 534.35)1567.64 (1289.72 to 1905.45)2421.31 (2072.82 to 2828.39)
Statistical analysis
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.87 · 95% CI 0.70 to 1.08
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.95 · 95% CI 0.74 to 1.22
  • 13vPnC After 2-Dose Infant Series vs 7vPnC After 2-Dose Infant Series · Ratio: 0.88 · 95% CI 0.68 to 1.13
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.69 · 95% CI 0.55 to 0.86
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.85 · 95% CI 0.68 to 1.07
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Ratio: 0.65 · 95% CI 0.51 to 0.83
PrimaryPercentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose

Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose
percentage of participants13vPnC After 2-Dose Infant Series13vPnC Before Toddler Dose
Common Serotypes - Serotype 496.6 (93.6 to 98.4)66.9 (60.6 to 72.9)
Common Serotypes - Serotype 6B58.4 (52.2 to 64.4)76.3 (70.3 to 81.6)
Common Serotypes - Serotype 9V94.7 (91.2 to 97.1)70.5 (64.2 to 76.2)
Common Serotypes - Serotype 1494.2 (90.6 to 96.7)94.4 (90.6 to 97.0)
Common Serotypes - Serotype 18C92.4 (88.5 to 95.3)53.0 (46.4 to 59.5)
Common Serotypes - Serotype 19F95.1 (91.7 to 97.3)92.4 (88.2 to 95.4)
Common Serotypes - Serotype 23F68.6 (62.6 to 74.1)32.3 (26.4 to 38.7)
Additional Serotypes - Serotype 196.6 (93.6 to 98.4)83.4 (78.0 to 87.9)
Additional Serotypes - Serotype 392.8 (89.0 to 95.6)30.8 (24.9 to 37.1)
Additional Serotypes - Serotype 591.6 (87.5 to 94.6)87.3 (82.4 to 91.3)
Additional Serotypes - Serotype 6A86.5 (81.8 to 90.4)86.4 (81.4 to 90.5)
Additional Serotypes - Serotype 7F98.5 (96.2 to 99.6)90.7 (86.3 to 94.1)
Additional Serotypes - Serotype 19A98.5 (96.1 to 99.6)96.2 (92.9 to 98.2)
PrimaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose
μg/mL13vPnC After 2-Dose Infant Series13vPnC Before Toddler Dose
Common Serotypes - Serotype 42.38 (2.11 to 2.67)0.53 (0.48 to 0.59)
Common Serotypes - Serotype 6B0.41 (0.36 to 0.47)0.61 (0.54 to 0.69)
Common Serotypes - Serotype 9V1.68 (1.51 to 1.86)0.48 (0.43 to 0.52)
Common Serotypes - Serotype 142.84 (2.44 to 3.31)2.03 (1.79 to 2.30)
Common Serotypes - Serotype 18C1.72 (1.54 to 1.93)0.35 (0.32 to 0.39)
Common Serotypes - Serotype 19F3.42 (2.95 to 3.97)0.94 (0.83 to 1.06)
Common Serotypes - Serotype 23F0.61 (0.53 to 0.71)0.26 (0.23 to 0.29)
Additional Serotypes - Serotype 12.30 (2.03 to 2.60)0.68 (0.61 to 0.75)
Additional Serotypes - Serotype 31.15 (1.04 to 1.28)0.25 (0.22 to 0.27)
Additional Serotypes - Serotype 51.27 (1.14 to 1.41)0.88 (0.80 to 0.97)
Additional Serotypes - Serotype 6A1.17 (1.02 to 1.33)0.81 (0.72 to 0.92)
Additional Serotypes - Serotype 7F2.06 (1.88 to 2.26)0.76 (0.70 to 0.82)
Additional Serotypes - Serotype 19F2.87 (2.55 to 3.24)1.20 (1.06 to 1.35)
SecondaryPercentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose

Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the toddler dose (12 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose
percentage of participants13vPnC After Toddler Dose7vPnC After Toddler Dose
Common Serotypes - Serotype 4 (n=244,245)100.0 (98.5 to 100.0)100.0 (98.5 to 100.0)
Common Serotypes - Serotype 6B (n=243,243)100.0 (98.5 to 100.0)100.0 (98.5 to 100.0)
Common Serotypes - Serotype 9V (n=235,248)100.0 (98.4 to 100.0)100.0 (98.5 to 100.0)
Common Serotypes - Serotype 14 (n=237,240)99.6 (97.7 to 100.0)99.6 (97.7 to 100.0)
Common Serotypes - Serotype 18C (n=245,245)99.2 (97.1 to 99.9)99.6 (97.8 to 100.0)
Common Serotypes - Serotype 19F (n=243,245)98.8 (96.4 to 99.7)98.4 (95.9 to 99.6)
Common Serotypes - Serotype 23F (n=240,243)99.2 (97.0 to 99.9)98.8 (96.4 to 99.7)
Additional Serotypes - Serotype 1 (n=244,240)99.6 (97.7 to 100.0)3.3 (1.4 to 6.5)
Additional Serotypes - Serotype 3 (n=245,218)93.9 (90.1 to 96.5)6.7 (3.9 to 10.6)
Additional Serotypes - Serotype 5 (n=245,243)100.0 (98.5 to 100.0)70.2 (63.6 to 76.2)
Additional Serotypes - Serotype 6A (n=243,243)99.6 (97.7 to 100.0)86.4 (81.5 to 90.5)
Additional Serotypes - Serotype 7F (n=242,243)99.6 (97.7 to 100.0)4.9 (2.6 to 8.5)
Additional Serotypes - Serotype 19A (n=241,241)100.0 (98.5 to 100.0)99.6 (97.7 to 100.0)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after toddler dose (12 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose
μg/mL13vPnC After Toddler Dose7vPnC After Toddler Dose
Common Serotypes - Serotype 4 (n=244,245)4.77 (4.29 to 5.30)7.08 (6.41 to 7.83)
Common Serotypes - Serotype 6B (n=243,243)10.00 (8.79 to 11.38)10.39 (9.14 to 11.82)
Common Serotypes - Serotype 9V (n=235,248)3.02 (2.74 to 3.32)4.10 (3.72 to 4.51)
Common Serotypes - Serotype 14 (n=237,240)10.30 (9.26 to 11.47)11.99 (10.77 to 13.35)
Common Serotypes - Serotype 18C (n=245,247)2.83 (2.55 to 3.14)4.26 (3.85 to 4.70)
Common Serotypes - Serotype 19F (n=243,245)9.01 (7.84 to 10.36)8.06 (7.06 to 9.21)
Common Serotypes - Serotype 23F (n=244,245)3.43 (3.02 to 3.88)4.87 (4.30 to 5.51)
Additional Serotypes - Serotype 1 (n=244,240)5.76 (5.12 to 6.47)0.03 (0.03 to 0.04)
Additional Serotypes - Serotype 3 (n=245,240)1.22 (1.09 to 1.35)0.07 (0.06 to 0.08)
Additional Serotypes - Serotype 5 (n=245,218)3.59 (3.25 to 3.96)0.56 (0.49 to 0.64)
Additional Serotypes - Serotype 6A (n=243,243)6.78 (6.04 to 7.61)1.42 (1.21 to 1.66)
Additional Serotypes - Serotype 7F (n=242,243)4.31 (3.94 to 4.72)0.04 (0.04 to 0.05)
Additional Serotypes - Serotype 19F (n=241,241)9.81 (8.82 to 10.92)4.24 (3.85 to 4.67)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—6/303 (2%)188/303 (62%)
7vPnC Infant Series—10/303 (3.3%)183/303 (60.4%)
13vPnC Post-Infant Series—8/294 (2.7%)96/294 (32.7%)
7vPnC Post-Infant Series—11/291 (3.8%)90/291 (30.9%)
13vPnC Toddler Series—3/287 (1%)165/287 (57.5%)
7vPnC Toddler Series—1/282 (0.4%)170/282 (60.3%)
13vPnC 6-Month Follow-up—9/290 (3.1%)1/290 (0.3%)
7vPnC 6-Month Follow-up—11/288 (3.8%)0/288 (0%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
GastroenteritisInfections and infestations1/3031/3033/2942/2910/2870/2820/2904/288
BronchiolitisInfections and infestations2/3033/3030/2940/2910/2870/2821/2900/288
VomitingGastrointestinal disorders0/3030/3031/2940/2912/2870/2821/2900/288
Febrile convulsionNervous system disorders0/3030/3032/2940/2911/2870/2822/2901/288
BronchopneumoniaInfections and infestations0/3030/3030/2942/2910/2870/2820/2900/288
DiarrhoeaGastrointestinal disorders0/3030/3030/2940/2911/2871/2820/2900/288
PyrexiaGeneral disorders0/3030/3030/2941/2910/2871/2820/2900/288
Gastroenteritis adenovirusInfections and infestations0/3030/3030/2940/2911/2870/2820/2900/288
Gastroenteritis rotavirusInfections and infestations0/3031/3030/2940/2911/2870/2820/2901/288
PharyngitisInfections and infestations0/3031/3030/2940/2911/2870/2820/2901/288
Most frequent other events
Showing 10 of 113
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
DiarrhoeaGastrointestinal disorders5/30312/3032/2945/58/2873/2820/2900/288
UrticariaSkin and subcutaneous tissue disorders0/3030/3030/2942/2911/10/2820/2900/288
IrritabilityGeneral disorders185/245183/243——————
IrritabilityGeneral disorders188/258165/259——165/221170/227——
Increased sleepGeneral disorders177/269178/276——105/195107/196——
Fever ≥38°C but ≤39°CGeneral disorders103/24795/246——130/204103/197——
Fever ≥38°C but ≤39°CGeneral disorders126/227137/226——————
Decreased appetiteGeneral disorders87/24685/248——103/198113/197——
Increased sleepGeneral disorders129/226131/232——————
Decreased appetiteGeneral disorders104/22099/218——————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.9 ± 0.32.9 ± 0.32.9 ± 0.3
Gender
Gender(participants)13vPnC7vPnCTotal
Female138133271
Male164170334
08

Study locations

13 sites
  • Napoli, Campania 80122, Italy
  • Napoli, Campania 80139, Italy
  • Bologna, Emilia Romagna 40138, Italy
  • Roma, Lazio 00100, Italy
  • Roma, Lazio 00165, Italy
  • Genova, Liguria 16132, Italy
  • Milan, Lombardia 20122, Italy
  • Novara, Piemonte 28100, Italy
  • Taranto, Puglia 74100, Italy
  • Sassari, Sardegna 07100, Italy
  • Ragusa, Sicilia 97100, Italy
  • Palermo, Sicillia 90100, Italy
  • Firenze, Toscana 50132, Italy
09

References and documents

Publications

  • Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinon-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16. PubMed 23965217 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 4 years 7 months after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2006
First posted
Aug 21, 2006
Start
Oct 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results delay requested
Feb 26, 2009
Results first posted
Feb 22, 2013
Last update
Feb 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00366899
Responsible party
Sponsor
First posted
Aug 21, 2006
Start date
Oct 2006
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Feb 22, 2013
Last update
Feb 22, 2013

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Italy, descresg@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion